By using a multiplex approach in which 92 oncology-related proteins can be tested simultaneously, we set out to identify biomarkers that can be used in combination with CA125 and HE4 to develop a highly sensitive and specific assay for the detection of early stage ovarian cancer. Here, MUC16 is linked to ovarian carcinoma.